First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.

Duncan A Wheatley Rossana Berardi Miguel A Climent Duran Anna Tomiak Alastair P Greystoke Anthony M Joshua Hendrick-Tobias Arkenau Lajos Géczi Javier García Corbacho Luis G Paz-Ares Syed Anwer HussainLubos PetruželkaAngelo Delmonte Colombe Chappey Joanna C Masters Elisabete Michelon Danielle A Murphy Sandrine Mwewa Rossano Cesari Bernard Doger

Published in: Cancer research communications (2024)

This phase Ib/II trial evaluated avelumab (immune checkpoint inhibitor) administered concurrently with standard first-line chemotherapy in patients with advanced urothelial carcinoma or advanced nonsquamous NSCLC without actionable mutations. Efficacy and safety appeared consistent with previous studies of similar combinations, although patient numbers were small.

Keyphrases

locally advanced
small cell lung cancer
clinical trial
case report
study protocol
rectal cancer
open label